What is HC Wainwright’s Forecast for PLRX FY2029 Earnings?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – HC Wainwright increased their FY2029 earnings estimates for shares of Pliant Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst E. Arce now expects that the company will earn $1.80 per share for the year, up from their prior forecast of $1.75. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.64) per share.

Several other research firms have also recently weighed in on PLRX. Stifel Nicolaus cut Pliant Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Royal Bank of Canada reduced their target price on shares of Pliant Therapeutics from $4.00 to $3.00 and set a “sector perform” rating on the stock in a report on Tuesday. Wells Fargo & Company decreased their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday. Needham & Company LLC reiterated a “hold” rating and set a $10.00 price target on shares of Pliant Therapeutics in a report on Tuesday. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $4.00 price objective (down previously from $43.00) on shares of Pliant Therapeutics in a research note on Monday, February 10th. Twelve equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.31.

Pliant Therapeutics Trading Up 2.5 %

Shares of PLRX stock opened at $1.62 on Thursday. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $98.58 million, a P/E ratio of -0.49 and a beta of 1.18. Pliant Therapeutics has a twelve month low of $1.26 and a twelve month high of $16.52. The stock’s fifty day simple moving average is $8.11 and its 200 day simple moving average is $11.50.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.17.

Insider Transactions at Pliant Therapeutics

In other Pliant Therapeutics news, CEO Bernard Coulie sold 52,419 shares of the stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $587,092.80. Following the completion of the sale, the chief executive officer now directly owns 430,517 shares in the company, valued at approximately $4,821,790.40. This trade represents a 10.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the transaction, the general counsel now directly owns 70,544 shares of the company’s stock, valued at approximately $775,278.56. This trade represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,855 shares of company stock worth $1,026,628 over the last three months. 6.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pliant Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PLRX. Frazier Life Sciences Management L.P. bought a new stake in shares of Pliant Therapeutics in the 4th quarter valued at $14,761,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Pliant Therapeutics by 18.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,574 shares of the company’s stock valued at $1,838,000 after purchasing an additional 21,637 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Pliant Therapeutics by 14.0% during the fourth quarter. Woodline Partners LP now owns 127,295 shares of the company’s stock valued at $1,676,000 after purchasing an additional 15,635 shares during the period. ProShare Advisors LLC raised its holdings in shares of Pliant Therapeutics by 31.8% during the fourth quarter. ProShare Advisors LLC now owns 18,931 shares of the company’s stock valued at $249,000 after purchasing an additional 4,570 shares during the period. Finally, Paradigm Biocapital Advisors LP boosted its position in shares of Pliant Therapeutics by 3.0% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,197,050 shares of the company’s stock worth $42,105,000 after purchasing an additional 92,564 shares in the last quarter. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.